Notable 52-Week Highs and Lows of the Day 10/15: (ABT) (CYCC) (AMT) High; (ADT) (ATML) Low
Get Alerts ABT Hot Sheet
Join SI Premium – FREE
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.
52-Week High:
52-Week High:
- Abbott Laboratories (NYSE: ABT) high of $71.99. Getting a boost from an update on its phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99 percent of treatment-naive (n=77) and 93 percent of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin for 12 weeks, based on an observed data analysis.
Shares moved up about 4 percent to the new mark.
- Cyclacel Pharma (Nasdaq: CYCC) high of $7.93. Cyclacel Pharma updated on an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza) and/or decitabine (Dacogen).
Survival rate numbers were robust. For more color, click here.
- American Tower (NYSE: AMT) high of $75.66. Moving higher chatter that Sprint (NYSE: S) might make a move to acquire more of Clearwire (Nasdaq: CLWR). Shares rose nearly 5 percent to the new mark Monday.
- Longwei Petroleum Investment Holding Ltd. (AMEX: LPH) high of $1.96. Earlier, Longwei announced that it has commenced operations at its Huajie fuel storage depot in northern Shanxi Province. Shares popped over 11 percent to the new high today.
- Cyclacel Pharma (Nasdaq: CYCC) high of $7.93. Cyclacel Pharma updated on an ongoing, multicenter, Phase 2 randomized trial of oral sapacitabine capsules, the Company's lead product candidate, in older patients with intermediate-2 or high-risk myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine (Vidaza) and/or decitabine (Dacogen).
- ADT (NYSE: ADT) low of $35.38. ADT slightly lower Monday. Earlier, Morgan Stanley started coverage on the company at Neutral, with a price target of $40. The target was just a 9.7 percent premium from last Friday's close at $36.48.
- Atmel (Nasdaq: ATML) low of $4.69. Atmel lower on continued downside momentum today. Over the last 17 sessions, Atmel closed lower for all but three.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- After-Hours Movers: AMAT, DLO, GLOB, YSS, ETON
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share